This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

In various embodiments a dental varnish system having improved peptide release and fluoride release properties is provided. In various embodiments a dental varnish system that provides release of an antimicrobial peptide, or specifically targeted antimicrobial peptide (STAMP), e.g., the peptide C16G2, is provided, with or without a fluoride. In various embodiments, a dental varnish system that provides release of a fluoride, with or without an antimicrobial peptide or STAMP is provided. In certain embodiments the dental varnish system comprises a first component that is a dry powder, said first component comprising a an antimicrobial peptide, with or without a fluoride, and a bulking agent, and a second component that is a fluid, said second component comprising a varnish solution, where combination of said first component with said second component provides a varnish formulation for application to the surface of a tooth.

An anti-tumor composition, comprising: (A) Bifidobacterium longum; and (B) an immune checkpoint inhibitor, such as a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. Also provided is a use of Bifidobacterium longum in preparing a drug for treating a tumor, wherein Bifidobacterium longum can be used in combination with an immune checkpoint inhibitor preparation.

An anti-tumor composition, comprising: (A) Bifidobacterium longum; and (B) an immune checkpoint inhibitor, such as a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. Also provided is a use of Bifidobacterium longum in preparing a drug for treating a tumor, wherein Bifidobacterium longum can be used in combination with an immune checkpoint inhibitor preparation.

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.

The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.

The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.